8-K: Wiley Appoints Dr. Karen N. Madden to Board of Directors
Director Appointment
Wiley has appointed Dr. Karen N. Madden, Chief Technology Officer at MilliporeSigma, to its Board of Directors, effective February 28, 2025.
Summary
- John Wiley & Sons, Inc. has announced the appointment of Dr. Karen N. Madden to its Board of Directors.
- Dr. Madden's appointment became effective on February 28, 2025.
- She will also serve on the Audit Committee of the Board.
- As a non-employee director, Dr. Madden will receive an annual cash retainer of $85,000 and an annual award of restricted Class A Common Stock equal to $130,000.
- The restricted shares will vest on the earliest of the day before the next Annual Meeting, her death or disability, or a Change in Control.
- Dr. Madden is currently the Senior Vice President and Chief Technology Officer at MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.
- In 2023, Merck KGaA, Darmstadt, Germany, generated sales of 21 billion in 65 countries.
Sentiment
Score: 7
Explanation: The announcement is positive, highlighting the addition of a qualified individual to the Board. It suggests a forward-looking approach to innovation and technology.
Positives
- The addition of Dr. Madden brings extensive experience in science, technology, and innovation to Wiley's Board.
- Her background at MilliporeSigma and PerkinElmer provides valuable insights into the research and development process.
- Dr. Madden's involvement with the global scientific community can strengthen Wiley's relationships with key stakeholders.
- Her appointment reflects Wiley's commitment to advancing knowledge and innovation.
Future Outlook
Wiley expects Dr. Madden's expertise to be invaluable as they continue to transform their business and deliver trusted content and services.
Management Comments
- Matthew Kissner, President & CEO of Wiley, stated that Dr. Madden's experience in science, technology, and innovation makes her an exceptional addition to the Board.
- Jesse Wiley, Board Chair, mentioned that Dr. Madden's knowledge in R&D and innovation will be tremendously valuable to Wiley.
Industry Context
The appointment of a technology leader from the life science industry reflects the increasing importance of technology and innovation in the publishing and knowledge services sector. Wiley is positioning itself to leverage data and technology to better serve its customers and partners.
Comparison to Industry Standards
- Wiley's board compensation structure, including cash retainers and stock awards, is generally in line with industry standards for publicly traded companies of similar size and scope.
- MilliporeSigma, where Dr. Madden serves as CTO, is a major player in the life science industry, comparable to companies like Thermo Fisher Scientific and Danaher Corporation.
- PerkinElmer, where Dr. Madden previously served as Senior Vice President and Chief Innovation Officer, is a global company focused on diagnostics, life sciences, and environmental and food testing.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board of Directors | Karen N. Madden, Ph.D. | February 28, 2025 | Appointment to the Board |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Committee Appointment | Dr. Madden has been appointed to the Audit Committee of the Board. | February 28, 2025 | Strengthens the Audit Committee with Dr. Madden's expertise. |
Stakeholder Impact
- Shareholders: The appointment of a qualified director can positively influence investor confidence.
- Employees: Dr. Madden's expertise may contribute to innovation and growth opportunities within the company.
- Customers: Enhanced innovation and technology may lead to improved products and services.
Key Dates
| Date | Description |
|---|---|
| February 28, 2025 | Effective date of Dr. Karen N. Madden's appointment to the Board of Directors. |
| March 5, 2025 | Date of the press release announcing Dr. Madden's appointment. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.